VITRAKVI

Trials studying VITRAKVI

• —Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Bodyrecruitingn=150
• —NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genesrecruitingn=100
• phase1A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancercompletedn=75
• phase2Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancerrecruitingn=13
• phase2A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumorscompletedn=215
• phase2A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Childrenactive not recruitingn=154
• —A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Databasecompletedn=93
• —A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practicecompletedn=368